AU6228000A - The use of retinoid receptor antagonists in the treatment of prostate carcinoma - Google Patents

The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Info

Publication number
AU6228000A
AU6228000A AU62280/00A AU6228000A AU6228000A AU 6228000 A AU6228000 A AU 6228000A AU 62280/00 A AU62280/00 A AU 62280/00A AU 6228000 A AU6228000 A AU 6228000A AU 6228000 A AU6228000 A AU 6228000A
Authority
AU
Australia
Prior art keywords
treatment
receptor antagonists
prostate carcinoma
retinoid receptor
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62280/00A
Inventor
Geoffrey Brown
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU6228000A publication Critical patent/AU6228000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62280/00A 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma Abandoned AU6228000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14528799P 1999-07-23 1999-07-23
US60145287 1999-07-23
PCT/US2000/019849 WO2001007028A2 (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Publications (1)

Publication Number Publication Date
AU6228000A true AU6228000A (en) 2001-02-13

Family

ID=22512422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62280/00A Abandoned AU6228000A (en) 1999-07-23 2000-07-21 The use of retinoid receptor antagonists in the treatment of prostate carcinoma

Country Status (2)

Country Link
AU (1) AU6228000A (en)
WO (1) WO2001007028A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416933A (en) 2003-11-25 2007-01-16 Novo Nordisk As compound, pharmaceutical composition, method for treating a disease, use of a compound, and methods for increasing mitochondrial respiration in a patient, and for reducing the amount of reactive oxygen species in a patient.
PT1937244T (en) 2005-09-30 2018-11-07 Io Therapeutics Llc Treatment of cancer with specific rxr agonists
MX352727B (en) 2011-12-13 2017-12-06 Dartmouth College Autoimmune disorder treatment using rxr agonists.
US10092535B2 (en) 2015-10-31 2018-10-09 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
KR102549273B1 (en) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
AU2016396659B2 (en) 2016-03-10 2019-02-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
TW201920081A (en) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 Carboxamides as modulators of sodium channels
JP2020526551A (en) 2017-07-13 2020-08-31 アイオー セラピューティクス インコーポレイテッド Immunomodulatory retinoid and lexinoid compounds combined with immunomodulators for cancer immunotherapy
CN111148514A (en) 2017-08-31 2020-05-12 Io治疗公司 RAR selective agonists combined with immunomodulators for cancer immunotherapy
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) * 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity

Also Published As

Publication number Publication date
WO2001007028A3 (en) 2001-08-30
WO2001007028A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
AU1293101A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
HRP20060251B1 (en) Substituted oxasolidinones and their use
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
IL147655A0 (en) Applicator for use in reflexotherapy
AU6228000A (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
AU4923200A (en) Isothiazolecarboxamides and their use as microbicides
AU3086900A (en) Device for the complex treatment of disorders of the prostate
HK1043059A1 (en) Tumor necrosis factor antagonists and their use inendometriosis.
AU5497000A (en) Non-malignant disease treatment with ras antagonists
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
HUP0202339A3 (en) Use of cortisol antagonists in the treatment of heat failure
AU2193797A (en) Delivery of therapeutic agents to the prostate
AU2297201A (en) Uses of antileukoprotease in carcinoma
AU3843600A (en) Bath equipped with water vibrator and therapeutic method using the same
GB2356362A9 (en) Ultrasonic nebuliser
GB9812662D0 (en) Therapeutic use
GB9929772D0 (en) New use
AU2001285707A1 (en) Peptides of the alpha1-adrenergic receptor and their use for psoriasis
GB9911238D0 (en) Therapeutic use
GB9900364D0 (en) Multifilar double-star micometer
GB9923117D0 (en) Insect-paper and methods for its formation and use
AU2021700A (en) Methods of using temozolomide in the treatment of cancers
TW392510U (en) Ultrasonic atomizing device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase